Mehdi Taghipour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11604842/publications.pdf

Version: 2024-02-01

516561 580701 25 699 16 25 citations g-index h-index papers 25 25 25 1128 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Utilizing dual energy CT to distinguish blood from contrast leakage following middle meningeal artery embolization for chronic subdural hematomas. Journal of NeuroInterventional Surgery, 2021, 13, 964-967.	2.0	3
2	Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 +â€9 prostate cancer. Abdominal Radiology, 2019, 44, 279-285.	%3 1.0	24
3	Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdominal Radiology, 2019, 44, 1520-1527.	1.0	28
4	Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. Clinical Nuclear Medicine, 2017, 42, e227-e234.	0.7	34
5	Post-treatment 18F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma. Nuclear Medicine Communications, 2017, 38, 250-258.	0.5	4
6	Classification of clinical significance of MRI prostate findings using 3D convolutional neural networks. Proceedings of SPIE, 2017, 10134, .	0.8	42
7	Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up ¹⁸ F-FDG PET/CT Scans in Oncology Patients. Journal of Nuclear Medicine, 2017, 58, 737-743.	2.8	10
8	Molecular Imaging and Precision Medicine. PET Clinics, 2017, 12, 105-118.	1.5	16
9	18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma. Nuclear Medicine Communications, 2016, 37, 231-238.	0.5	28
10	Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. Nuclear Medicine Communications, 2016, 37, 602-608.	0.5	2
11	Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma. Clinical Nuclear Medicine, 2016, 41, e93-e97.	0.7	4
12	The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma. Nuclear Medicine Communications, 2016, 37, 699-704.	0.5	3
13	FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. American Journal of Roentgenology, 2016, 206, 846-855.	1.0	15
14	FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. Oncologist, 2016, 21, 931-939.	1.9	174
15	JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival. American Journal of Roentgenology, 2016, 207, 257-265.	1.0	15
16	18F-FDG PET/CT and Melanoma. Clinical Nuclear Medicine, 2016, 41, e403-e409.	0.7	18
17	FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. American Journal of Roentgenology, 2016, 206, 1093-1100.	1.0	16
18	¹⁸ F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. Journal of Nuclear Medicine, 2016, 57, 855-860.	2.8	40

#	Article	IF	CITATION
19	Use of ¹⁸ F-Fludeoxyglucose–Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 79.	1.2	27
20	The value of followâ€up <scp>FDGâ€PET</scp> / <scp>CT</scp> in the management and prognosis of patients with <scp>HPV</scp> â€positive oropharyngeal squamous cell carcinoma. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 681-686.	0.9	17
21	¹⁸ F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. Journal of Nuclear Medicine, 2015, 56, 989-994.	2.8	15
22	Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. PET Clinics, 2015, 10, 265-278.	1.5	20
23	FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas. PET Clinics, 2015, 10, 327-343.	1.5	36
24	Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. PET Clinics, 2015, 10, 375-393.	1.5	28
25	Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2015, 205, 629-639.	1.0	80